Answers are grounded in this paper and cite their sources.
Gold nanoparticles (AuNPs) have emerged as promising nanocarriers for advanced drug delivery because of their distinctive physicochemical properties, tunable size and morphology, high surface-to-volume ratio, excellent surface chemistry, and unique optical characteristics. Their surfaces can be readily modified with polymers, biomolecules, targeting ligands, and therapeutic agents, enabling the development of multifunctional delivery systems with improved drug solubility, stability, cellular uptake, and controlled release. Various synthesis approaches, including chemical reduction, seed-mediated growth, green synthesis, photochemical reduction, and physical methods, have been developed to produce AuNPs with controlled dimensions, shapes, and surface characteristics. Among these, chemical reduction remains widely employed because of its simplicity and reproducibility, whereas green synthesis has attracted increasing interest as an environmentally friendly alternative using plant extracts, microorganisms, and naturally occurring biomolecules. Following synthesis, AuNPs can be functionalized using thiol chemistry, polymer coating, electrostatic interactions, and covalent conjugation to facilitate drug encapsulation or attachment. These engineered nanocarriers have demonstrated potential in cancer chemotherapy, antimicrobial treatment, gene delivery, and combination therapy. Furthermore, stimuli-responsive AuNP systems can facilitate localized drug release in response to pH, temperature, light, and other biological or external stimuli. Despite substantial progress, challenges related to long-term toxicity, biodistribution, immune responses, biodegradation, manufacturing reproducibility, and clinical translation remain. This review provides a comprehensive overview of AuNP synthesis strategies, surface engineering, drug-loading mechanisms, and therapeutic applications, while discussing the major limitations and future opportunities for developing safe, effective, and clinically translatable gold-based nanomedicines.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: